We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Aspergillus PCR Early Detection in High Risk Oncohematological Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01742026
Recruitment Status : Unknown
Verified December 2012 by Grupo Espanol de trasplantes hematopoyeticos y terapia celular.
Recruitment status was:  Active, not recruiting
First Posted : December 5, 2012
Last Update Posted : December 5, 2012
Sponsor:
Information provided by (Responsible Party):

Study Description
Brief Summary:
ADVANCE THERAPY ASPERGILLOSIS INVASIVE BY PCR DETECTION

Condition or disease Intervention/treatment Phase
Infections Procedure: Aspergillus PCR technique Procedure: Aspergillus AGA technique Phase 4

Detailed Description:
ADVANCE THERAPY ASPERGILLOSIS INVASIVE IN PATIENTS HIGH RISK ONCOHEMATOLOGICAL PCR USING FOR EARLY DETECTION OF ASPERGILLUS

Study Design

Study Type : Observational
Actual Enrollment : 225 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: ADVANCE THERAPY ASPERGILLOSIS INVASIVE IN PATIENTS HIGH RISK ONCOHEMATOLOGICAL PCR USING FOR EARLY DETECTION OF ASPERGILLUS
Study Start Date : February 2011
Estimated Study Completion Date : December 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Aspergillosis
U.S. FDA Resources

Groups and Cohorts

Group/Cohort Intervention/treatment
High Risk Oncohematological Patients
Detection Aspergillus PCR technique and Aspergillus AGA technique
Procedure: Aspergillus PCR technique
Aspergillus DNA PCR technique
Procedure: Aspergillus AGA technique
Aspergillus AGA technique


Outcome Measures

Primary Outcome Measures :
  1. Efficacy of PCR technique for detection of Aspergillus DNA versus the standard technique for the determination of galactomannan Antigen (AGA) in serum [ Time Frame: 18-20 months ]
    To value the percentage of patients with likely/proven invasive fungal infection, diagnosed using only AGA tecnique or using AGA and PCR tecniques together.


Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
The study population will consist of hematological patients at high risk of invasive fungal infection. Like: Leukemia acute mieloblasticas, myelodysplastic syndrome, patients with intensive chemotherapy and allogeneic hematopoietic transplantation.
Criteria

Inclusion Criteria:

  • Signature of informed consent to participate in the study.
  • Adult patients (> 18 years), diagnosed with acute myelogenous leukemia or myelodysplastic syndrome with chemotherapy (CT) intensive, or admitted to undergo allogeneic hematopoietic progenitor cells, or transplantation with graft versus host disease.
  • The patient should be included in this protocol from the start of their chemotherapy or conditioning therapy as reflected in another section.

Exclusion Criteria:

  • Employment of antifungal prophylaxis (30 days prior to inclusion) with triazole / polyene with activity against Aspergillus (itraconazole, voriconazole, posaconazole, amphotericin B inhalation).
  • Use of other systemic antifungal activity against Aspergillus (amphotericin, terbinafine, flucytosine, echinocandins, etc.). Therefore it will Fluconazole prophylaxis exclusively.
  • Background of IFI proven / probable prior
  • Probable IFI / tested at the time of inclusion in the study.
  • Exclusion will cause a lack of compliance with the inclusion criteria.
  • Patients who have a lack of follow biweekly with galactomannan or PCR. Have a bacterial infection not properly treated and controlled before starting empirical antifungal treatment (according to the definition given above). And finally they have a neutropenia of short duration that it creates a significant risk of IFI. This information will not be known logically to include the patient in the study.
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01742026


Locations
Spain
Hospital Germans Trias i Pujol
Badalona, Barcelona, Spain, 08916
Complejo Hospitalario de A Coruña
A Coruña, Spain, 15006
Hospital Vall d´Hebron
Barcelona, Spain, 08035
Hospital Clinic de Barcelona
Barcelona, Spain, 08036
Hospital Josep Trueta
Girona, Spain, 17007
Hospital Ramon y Cajal
Madrid, Spain, 28034
Hospital Clinico San Carlos
Madrid, Spain, 28040
Hospital morales Meseguer
Murcia, Spain, 30008
Hospital Central de Asturias
Oviedo, Spain, 33006
Hospital Universitario de Salamanca
Salamanca, Spain, 37007
Hospital Virgen del Rocio
Sevilla, Spain, 41013
Hospital Clinico de Valencia
Valencia, Spain, 46010
Hospital Clinico Lozano Blesa
Zaragoza, Spain, 50009
Sponsors and Collaborators
Grupo Espanol de trasplantes hematopoyeticos y terapia celular
Investigators
Principal Investigator: Lourdes Vazquez, MD Hospital Universitario de Salamanca
Principal Investigator: Isabel Ruiz, Md Hospital Vall d´Hebron
Principal Investigator: Rocio Parody, MD Hospital Virgen del Rocio
Principal Investigator: Javier Lopez, MD Hospital Ramon y Cajal
Principal Investigator: Montserrat Rovira, MD Hospital Clinic of Barcelona
Principal Investigator: Montserrat Batlle, MD Germans Trias i Pujol Hospital
Principal Investigator: Carlos Vallejo, MD Hospital Central de Asturias
Principal Investigator: Rosario Varela, MD Hospital de A Coruña
Principal Investigator: Inmaculada Heras, MD Hospital Morales Meseguer
Principal Investigator: Joaquin Diaz, MD Hospital Clinico San Carlos
Principal Investigator: Carlos Solano, MD Hospital Clinico de Valencia
Principal Investigator: Maria Teresa Olave, MD Hospital Lozano Blesa
Principal Investigator: David Gallardo, MD H. Josep Trueta
More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Grupo Espanol de trasplantes hematopoyeticos y terapia celular
ClinicalTrials.gov Identifier: NCT01742026     History of Changes
Other Study ID Numbers: GETH-PCRAGA
First Posted: December 5, 2012    Key Record Dates
Last Update Posted: December 5, 2012
Last Verified: December 2012

Keywords provided by Grupo Espanol de trasplantes hematopoyeticos y terapia celular:
High risk aspergillosis infection patients

Additional relevant MeSH terms:
Aspergillosis
Mycoses
Hyalohyphomycosis
Dermatomycoses
Lung Diseases, Fungal
Skin Diseases, Infectious
Skin Diseases